Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01623349 |
| Title | Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Dana-Farber Cancer Institute |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States | Details | |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | United States | Details | |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | United States | Details | |
| MD Anderson Cancer Center | Houston | Texas | 77230 | United States | Details |